Drug Profile


Alternative Names: MSC Apceth; MSC_Apceth

Latest Information Update: 21 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apceth
  • Class Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Peripheral arterial occlusive disorders

Most Recent Events

  • 17 Sep 2015 Phase-II clinical trials in Peripheral arterial occlusive disorders in Germany (IV)
  • 12 Jul 2013 Alecmestencel-T is available for licensing as of 12 Jul 2013.
  • 01 Mar 2011 Phase-I/II clinical trials in Peripheral arterial occlusive disorders in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top